Simon Dixon

THE DEADLY IMPACT OF CORONARY PERFORATION IN WOMEN UNDERGOING PCI: INSIGHTS FROM BMC2

We evaluated the incidence, risk factors, outcomes and predictors of mortality of the rare but serious complication of coronary artery perforations (CAP).nn151,479 patients who underwent percutaneous coronary intervention (PCI) were included. Endpoints included the development of CAP, in-hospital

THE SAFETY OF PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS TURNED DOWN FOR SURGICAL REVASCULARIZATION: INSIGHTS FROM THE BLUE CROSS BLUE SHIELD OF MICHIGAN CARDIOVASCULAR CONSORTIUM

Surgical ineligibility (SI) is associated with increased mortality after left main or multi vessel percutaneous coronary intervention (PCI). We compared outcomes after PCI between patients (pts) turned down and not turned down for surgery in a diverse cohort of pts and practices.nnWe included

READMISSION AND LONG-TERM MORTALITY IN OLDER PATIENTS TREATED WITH TICAGRELOR VERSUS PRASUGREL AFTER PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE BLUE CROSS BLUE SHIELD OF MICHIGAN CARDIOVASCULAR CONSORTIUM

Background: In randomized trials, ticagrelor and prasugrel were superior to clopidogrel in the treatment of acute coronary syndrome (ACS); however, the comparative effectiveness of these two drugs in real-world practice remains unknown. We compared post-discharge outcomes among older pts discharged

OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION AMONG PATIENTS WITH A HISTORY OF TRANSIENT ISCHEMIC ATTACK OR CEREBROVASCULAR ACCIDENT: INSIGHTS FROM THE BLUE CROSS BLUE SHIELD OF MICHIGAN CARDIOVASCULAR CONSORTIUM

Background: Due to shared risk factors between coronary artery disease and cerebrovascular disease, patients (pts) with a history of transient ischemic attack (TIA) or cerebrovascular accident (CVA) often undergo percutaneous coronary intervention (PCI). We examined the association between a history

ARE HIGHER HOSPITAL APPROPRIATENESS SCORES FOR PERCUTANEOUS CORONARY INTERVENTION LINKED TO FEWER 30-DAY READMISSIONS?

Institutional programs aimed at improving PCI appropriateness may impact care delivery through better process control, measurement, and infrastructure, potentially affecting other outcomes like 30-day readmissions.nnThis retrospective cohort study included 31 hospitals performing both elective and

THE CONSEQUENCES OF HEPARIN USE IN PRIMARY PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE BLUE CROSS BLUE SHIELD OF MICHIGAN CARDIOVASCULAR CONSORTIUM (BMC2)

Heparin is commonly used as the sole procedural anticoagulant in patients undergoing primary PCI (PPCI). Use of Bivalirudin compared with platelet glycoprotein IIbIIIa inhibitors (GPI) has been associated with improved survival in this cohort. There are no data on the comparative effectiveness of

THE COMPARATIVE EFFECTIVENESS OF BIVALIRUDIN AND PLATELET GLYCOPROTEIN IIBIIIA INHIBITORS AMONG PATIENTS UNDERGOING CONTEMPORARY PRIMARY PCI: INSIGHTS FROM THE BLUE CROSS BLUE SHIELD OF MICHIGAN CARDIOVASCULAR COLLABORATIVE (BMC2)

Bivalirudin compared with platelet glycoprotein IIbIIIa inhibitors (GPI) was associated with reduced bleeding, increased stent thrombosis and improved survival in patients undergoing primary PCI (PPCI) in the HORIZONS AMI trial. These findings have not been externally corroborated.nnOur study cohort

LACK OF ASPIRIN USE PRIOR TO PCI IS RELATIVELY COMMON AND STRONGLY ASSOCIATED WITH INCREASED IN–HOSPITAL MORTALITY

Aspirin (ASA) is an essential component of peri–percutaneous coronary intervention (PCI) pharmacotherapy. Prior studies suggest that ASA is not administered to a small but clinically significant number of patients before undergoing PCI.nnWe evaluated the incidence of PCIs performed without pre–